Relationship Between Serum Neopterin Level and Peripheral Arterial Plaque in Patients with Type 2 Diabetes

Ren-Hui Wan\textsuperscript{1} 
Yang Yuan\textsuperscript{2} 
Wei Hao\textsuperscript{1} 
Long-Yi Zheng\textsuperscript{1,*} 
Jin Lu\textsuperscript{1,*}

\textsuperscript{1}Department of Endocrinology, Changhai Hospital, Second Military Medical University, Shanghai, People’s Republic of China; \textsuperscript{2}Laboratory of Cardiothoracic Surgery Department, Changhai Hospital, Second Military Medical University, Shanghai, People’s Republic of China

\*These authors contributed equally to this work

Objective: Neopterin is an inflammatory factor synthesized by monocyte macrophages in response to γ-interferon. It plays an important role in regulating a variety of physiological and pathological processes, including obesity, diabetes, and cardiovascular disease. This study aims to clarify the relationship between peripheral arterial plaque and serum neopterin in type 2 diabetes.

Methods: We consecutively selected 121 inpatients with type 2 diabetes. After collecting relevant clinical indicators, we collected serum from all patients and measured neopterin levels through enzyme linked immune sorbent assay. Peripheral arterial plaques (the carotid and femoral arteries) were detected by B-mode ultrasound. Multivariate logistic regression was used to determine the independent influencing factors. The correlation between neopterin levels and other variables was analyzed by Spearman correlation analysis. P < 0.05 was considered to be statistically significant.

Results: There was no difference in serum neopterin levels between arterial plaques group and no plaques group. Serum neopterin levels in patients with carotid plaque were elevated compared to patients without carotid plaque. Logistic regression analysis showed that a higher serum neopterin level was an independent risk factor for the presence of carotid plaques. Serum neopterin levels were positively correlated with BMI, HOMA-IR, and serum creatinine and negatively correlated with eGFR.

Conclusion: Serum neopterin levels were positively and independently associated with carotid plaque in patients with type 2 diabetes.

Keywords: neopterin, carotid plaques, type 2 diabetes mellitus, atherosclerosis

Introduction

Along with the development of obesity, sedentary lifestyles, high-energy diets, and population aging, approximately 415 million adults worldwide had diabetes in 2015.\textsuperscript{1} Type 2 diabetes and its complications greatly exacerbate the burden of mortality and disability worldwide. Twenty-seven percentage of diabetes suffer from macrovascular complications,\textsuperscript{2} and macrovascular complications are the main cause of death in type 2 diabetes patients, accounting for 44% of all-cause mortality.\textsuperscript{3} Diabetes can cause atherosclerosis in all major vascular beds, including coronary, carotid, and lower extremity arteries.\textsuperscript{4} The mechanism of atherosclerosis in diabetes involves oxidative stress and inflammatory response of vascular endothelial cells.\textsuperscript{5} We have confirmed that visfatin serves as a risk factor for atherosclerotic plaques in type 2 diabetes.\textsuperscript{6} Studying the role of different
inflammatory mediators in peripheral arterial plaques will help clarify the exact pathogenesis of macrovascular complications in type 2 diabetes.

Neopterin is an inflammatory factor synthesized and released by monocyte macrophages in response to γ-interferon during inflammation. Multiple studies have verified that neopterin could promote atherosclerosis. The review considers that neopterin is a risk marker for cardiovascular disease, whether it is for unstable angina, acute myocardial infarction, or cardiovascular death. Increased serum neopterin levels are associated with relapse of acute coronary syndrome and hospitalization of heart failure. In vivo, neopterin may promote plaque growth and apoptosis of vascular smooth muscle cells induced by oxidative stress. Regarding the relationship between neopterin and diabetes, the serum neopterin levels in patients with diabetes are significantly higher than in healthy and prediabetic people. Serum neopterin appears to be related to impaired insulin secretion and insulin resistance in the development of T2D. Although neopterin has been regarded as a proinflammatory and proatherosclerotic agent, more recent research indicated that neopterin also prevents both vascular inflammation and atherosclerosis and may be induced to counteract the progression of atherosclerotic lesions. Therefore, the correlation between circulating neopterin levels and peripheral plaques in different vascular territories in type 2 diabetes needs to be further investigated.

This study aimed to explore the association between serum neopterin and peripheral arterial plaque in patients with type 2 diabetes and to analyze the difference in neopterin levels in different vascular territories.

Methods
Study Population
This cross-sectional study of a single-center cohort was conducted for patients with type 2 diabetes at Changhai Hospital in Shanghai, China. Totally 121 inpatients were consecutively recruited from December 2016 to February 2018. We excluded patients younger than 18 years old, with type 1 diabetes, gestational diabetes, special types of diabetes, acute complications of diabetes (diabetic ketoacidosis and diabetic hyperosmolar coma), acute inflammatory diseases, malignancy, and other endocrine diseases. This study was authorized by the Ethics Committee of Changhai Hospital. The study was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained before the data collection and analysis.

Clinical and Biochemical Assessment
The basic information (age, gender, diabetes duration) and anthropometric measurements (height, body weight, waist circumference, hip circumference) were collected according to standard measurement method. Laboratory data was measured from venous blood and urine samples, which were taken in the morning after an overnight fast of at least 10 h. Blood cell analysis (including white blood cell (WBC) count, total neutrophils, lymphocytes, and platelet count) was measured using the Sysmex XN-9000 analyzer (Sysmex Co., Kobe, Japan). Plasma glucose, serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ-glutamyl transpeptidase (GGT), bilirubin, total bile acid (TBA), blood urea nitrogen (BUN), serum creatinine, uric acid, estimated glomerular filtration rate (eGFR), lipid profile, including total cholesterol, triglycerides, HDL cholesterol (HDL-c), and LDL cholesterol (LDL-c) were performed on HITACHI 7600–120 automatic biochemical analyzer (Hitachi Co., Japan). Hemoglobin A1c (HbA1c) was measured by high-pressure liquid chromatography. Fasting blood glucose (FBG) and postprandial blood glucose (PBG) were measured by the glucose oxidase method. Insulin and C-peptide levels were measured with an automatic analyzer (Roche-E601, Roche Diagnostics, Germany). Urinary albumin-to-creatinine ratio (ACR) was measured using automatic urine microalbumin and creatinine analyzer.

Enzyme-Linked Immunosorbent Assay (ELISA)
Serum levels of neopterin were measured with commercially available enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer’s instructions (Raybiotech Inc., GA, USA). The intra-assay and inter-assay coefficients of variation were less than 10% in enzyme immunoassays.

Peripheral Artery Ultrasound Measurement
B-mode ultrasound of the carotid and femoral arteries was performed with the Philips re33 Ultrasound System (Philips Healthcare, Andover, MA). An experienced doctor who was blinded to clinical follow-up data accomplished the analysis of the presence of atherosomatic plaques. Arterial plaques were defined as having an...
intima-media thickness (IMT) ≥1.3 mm or a focal protrusion into the lumen with a thickness of at least 50% more than the adjacent intima-media complex.

Definitions
The diagnostic criteria for diabetes are strictly based on American Diabetes Association standards. Diabetes duration is calculated from the time when they were first diagnosed with type 2 diabetes. Body mass index (BMI) is defined as body weight(kg)/height(m)^2. Waist–hip ratio (WHR) is defined as waist circumference/hipline circumference. HOMA-IR is defined as fasting plasma glucose (mmol/L)×fasting insulin (mIU/L)/22.5. eGFR is calculated by the C-MDRD (modified for Chinese) equation: eGFR = 175 x (Serum Creatinine)^−1.234 x (Age)^−0.179 x (0.79 only if female).  

Statistical Analysis
Using SPSS 22.0 software, categorical data were expressed as proportion. Differences between groups were evaluated by χ^2-test. Measurement data of normal distribution were expressed as mean ± standard deviation (SD), while skewed distribution data were shown as medians (Q1–Q3). Independent-sample t test or Mann–Whitney U-test was used for comparison between groups. Multivariate Logistic regression was used to determine the independent influencing factors. The association between serum neopterin levels and other variables was analyzed using Spearman correlation analysis. P values <0.05 were considered to be statistically significant.

The sample size calculations for the comparison between the mean of two independent groups were performed with PASS 11 (β=0.8, α=0.05, μβ=0.84, μα=1.96, s1=1.45, s2=0.68, δ=0.68). The minimal sample size required for each group was 45 subjects.

Results
General Characteristics of the Study Subjects
Overall, our study included 121 patients with T2DM who were admitted to our hospital. All patients were then divided into two groups according to the presence or absence of carotid and/or femoral arteries plaques. No plaques in the carotid and/or femoral arteries were found in 41.3% (50/121) of patients. Unexpectedly, as shown in Supplemental Table S1, there was no difference in serum neopterin levels between these two groups. Serum neopterin also cannot serve as a predictor of plaques (Supplemental Table S2).
serum indirect bilirubin, alanine aminotransferase, aspartate aminotransferase, γ-Glutamyl transpeptidase, and total cholesterol were significantly lower in femoral arterial plaque group. There was no statistical difference in serum neopterin levels between the two groups (P=0.130). Multivariable logistic regression analysis revealed that serum neopterin levels were not independent risk factors for the presence of femoral plaques (Supplemental Table S5).

**Correlations Between Serum Neopterin Levels and Clinical Indicators**

In order to find out the relevant factors that affect the serum neopterin levels in patients with type 2 diabetes, the correlation between the serum neopterin levels and other clinical parameters was analyzed by Spearman correlation analysis. As shown in Table 4 and Supplemental Table S6, serum neopterin levels were positively correlated with BMI ($r_s=0.191$, $P=0.036$), serum creatinine ($r_s=0.327$, $P<0.001$), HOMA-IR ($r_s=0.184$, $P=0.043$), and negatively correlated with eGFR ($r_s=-0.358$, $P<0.001$).

**Discussion**

Neopterin is an inflammatory factor secreted by monocyte macrophages.\(^7\) In the past two decades, neopterin has received more and more attention in the pathogenesis of cardiovascular complications.\(^19\)–\(^21\) In diabetic patients, it is also confirmed that neopterin is an independent predictor for fatal ischemic heart disease.\(^22\)

---

**Table 1** Comparison of Carotid Plaque Group and No Carotid Plaque Group

| Variables                  | Carotid Plaque (n=48) | No Carotid Plaque (n=73) | P-value |
|----------------------------|-----------------------|--------------------------|---------|
| Age (years)                | 58.63±9.68            | 48.55±13.81              | <0.001  |
| Gender (male)              | 30(62.5%)             | 52(71.2%)                | 0.315   |
| Diabetes duration (years)  | 6(1.25–10)            | 3(1–9)                   | 0.146   |
| BMI (kg/m\(^2\))           | 27.89±3.03            | 27.77±4.26               | 0.861   |
| Waist-to-hip ratio         | 0.96±0.07             | 0.96±0.06                | 0.839   |
| Indirect bilirubin (µmol/L) | 7.5±3.12              | 9.68±4.42                | 0.002   |
| Direct bilirubin (µmol/L)  | 3.38±1.41             | 4.21±2.33                | 0.016   |
| Serum creatinine (µmol/L)  | 75.50±21.75           | 69.07±18.63              | 0.085   |
| eGFR (mL/min)              | 94.13±25.32           | 110.95±27.21             | 0.001   |
| Total cholesterol (mmol/L) | 4.68±1.51             | 5.36±2.21                | 0.064   |
| Triglycerides (mmol/L)     | 1.72(1.27–2.86)       | 1.57(1.20–3.09)          | 0.761\(^*\) |
| HDL cholesterol (mmol/L)   | 1.00±0.22             | 1.09±0.34                | 0.070   |
| LDL cholesterol (mmol/L)   | 2.75±1.05             | 2.87±1.22                | 0.565   |
| ACR (mg/g)                 | 17.5(5.25–134.25)     | 10(5–41)                 | 0.300\(^*\) |
| Fasting plasma glucose (mmol/L) | 9.19±2.90            | 9.47±3.22                | 0.630   |
| 1h postprandial plasma glucose (mmol/L) | 15.90±4.08 | 16.10±3.89               | 0.782   |
| 2h postprandial plasma glucose (mmol/L) | 18.23±4.01 | 17.86±4.50               | 0.646   |
| Fasting insulin (mIU/L)    | 13.1(6.85–18.95)      | 11.4(7.05–17.0)          | 0.433\(^*\) |
| Fasting C-peptide (µg/L)   | 2.37(1.82–3.34)       | 2.50(1.56–3.13)          | 0.649\(^*\) |
| 1h postprandial insulin (mIU/L) | 25.3(16.05–56.95)    | 28.0(13.15–45.2)         | 0.578\(^*\) |
| 1h postprandial C-peptide (µg/L) | 3.62(2.72–5.96)    | 3.35(2.36–4.97)          | 0.395\(^*\) |
| 2h postprandial insulin (mIU/L) | 31.25(13.68–56.28)  | 29.3(15.35–36.35)        | 0.801\(^*\) |
| 2h postprandial C-peptide (µg/L) | 4.59(3.38–7.17)    | 4.78(3.04–6.53)          | 0.494\(^*\) |
| HOMA-IR                    | 4.68(3.25–8.33)       | 4.62(3.00–8.06)          | 0.468\(^*\) |
| Hemoglobin A1c (%)         | 9.61±1.89             | 9.53±2.18                | 0.852   |
| Neopterin (ng/mL)          | 2.02(1.57–2.89)       | 1.80(1.48–2.26)          | 0.026\(^*\) |

Notes: \(^*\) compared by the Mann–Whitney test.

**Table 2** Independent Factors for Carotid Plaques by Multivariable Logistic Regression Analysis

| Parameters                  | OR (95% CI) | P-value |
|----------------------------|-------------|---------|
| Age                        | 1.061(1.020,1.104) | 0.003   |
| Direct bilirubin           | 0.853(0.578,1.258) | 0.422   |
| Indirect bilirubin         | 0.908(0.758,1.087) | 0.293   |
| eGFR                       | 0.990(0.973,1.007) | 0.246   |
| Neopterin                  | 1.689(1.006,2.834) | 0.047   |

Abbreviations: OR, odds ratio; CI, confidence interval; eGFR, estimated glomerular filtration rate.
Diabetes mellitus is a major risk factor for peripheral artery disease. In this study, we tried to establish an association between peripheral arterial plaques, as detected by ultrasonography, in two different territories, including the carotid and femoral arteries, and the serum neopterin levels. According to our results, serum neopterin levels in type 2 diabetes patients with carotid plaque were significantly higher than group without carotid plaque. Interestingly, there was no statistical difference in the levels of neopterin between femoral arterial plaque group and no femoral arterial plaque group. The difference between the carotid arterial plaque group and the femoral arterial plaque group may attribute to the plaque composition. The area and number of macrophages in carotid arterial plaque are higher than those in femoral arterial plaque, while neopterin is secreted by activated macrophage. Except for macrophages, the distribution of other inflammatory molecular markers is different in carotid and femoral atherosclerotic plaques.

**Table 3** The Comparison of Femoral Plaque Group and No Femoral Plaque Group

| Variables                  | Femoral Plaque (n=52) | No Femoral Plaque (n=69) | P-value |
|----------------------------|-----------------------|--------------------------|---------|
| Age (years)                | 58.31±10.38           | 48.20±13.58              | <0.001  |
| Gender (male)              | 38(73.1%)             | 44(63.8%)                | 0.278   |
| Diabetes duration (years)  | 6(2–11.75)            | 3(0.54–8)                | 0.027*  |
| BMI (kg/m²)                | 27.36±2.79            | 28.16±4.41               | 0.228   |
| Waist-to-hip ratio         | 0.96±0.06             | 0.96±0.07                | 0.941   |
| Indirect bilirubin (μmol/L)| 7.92±2.93             | 9.49±4.68                | 0.026   |
| Direct bilirubin (μmol/L)  | 3.51±1.17             | 4.17±2.49                | 0.058   |
| Serum creatinine (μmol/L)  | 74.29±21.62           | 69.61±18.76              | 0.206   |
| eGFR (mL/min)              | 98.99±26.58           | 108.26±27.93             | 0.068   |
| Total cholesterol (mmol/L) | 4.56±1.47             | 5.49±2.23                | 0.010   |
| Triglycerides (mmol/L)     | 1.62(1.15–2.86)       | 1.77(1.26–3.35)          | 0.316*  |
| HDL cholesterol (mmol/L)   | 1.03±0.33             | 1.08±0.28                | 0.435   |
| LDL cholesterol (mmol/L)   | 2.61±1.10             | 2.98±1.17                | 0.084   |
| ACR (mg/g)                 | 12(4.25–126.75)       | 11(5–45.57)              | 0.755*  |
| Fasting plasma glucose (mmol/L) | 8.91±2.49      | 9.70±3.45                | 0.165   |
| 1h postprandial plasma glucose (mmol/L) | 15.96±3.75 | 16.07±4.12                | 0.889   |
| 2h postprandial plasma glucose (mmol/L) | 18.14±3.85 | 17.91±4.64                | 0.777   |
| Fasting insulin (mIU/L)    | 12.1(6.78–18.95)      | 12.2(7.4–17.6)           | 0.900*  |
| Fasting C-peptide (μg/L)   | 2.47(1.77–3.14)       | 2.41(1.61–3.20)          | 0.992*  |
| 1h postprandial insulin (mIU/L) | 28.07(19.0–63.08)   | 23.8(11.85–45.2)         | 0.079*  |
| 1h postprandial C-peptide (μg/L) | 3.67(2.44–5.80) | 3.32(2.38–4.91)          | 0.250*  |
| 2h postprandial insulin (mIU/L) | 30.95(17.55–61.93)   | 26.4(13.2–50.15)         | 0.124*  |
| 2h postprandial C-peptide (μg/L) | 4.75(3.33–7.13)   | 4.56(2.97–6.53)          | 0.308*  |
| HOMA-IR                    | 4.55(2.92–7.98)       | 4.80(3.10–8.83)          | 0.755*  |
| Hemoglobin A1c (%)         | 9.32±1.86             | 9.75±2.20                | 0.261   |
| Neopterin (ng/mL)          | 2.00(1.56–2.71)       | 1.80(1.51–2.28)          | 0.130*  |

Notes: *compared by the Mann–Whitney test.

**Table 4** Correlation of Neopterin Levels and Clinical Variables

| Parameters                  | Neopterin | P-value |
|----------------------------|-----------|---------|
| BMI                        | 0.191     | 0.036   |
| Serum creatinine           | 0.327     | <0.001  |
| eGFR                       | -0.358    | <0.001  |
| HOMA-IR                    | 0.184     | 0.043   |

**Abbreviations:** BMI, body mass index; eGFR, estimated glomerular filtration rate.

Diabetes mellitus is a major risk factor for peripheral artery disease. In this study, we tried to establish an association between peripheral arterial plaques, as detected by ultrasonography, in two different territories, including the carotid and femoral arteries, and the serum neopterin levels. According to our results, serum neopterin levels in type 2 diabetes patients with carotid plaque were significantly higher than group without carotid plaque. Interestingly, there was no statistical difference in the levels of neopterin between femoral arterial plaque group and no femoral arterial plaque group. The difference between the carotid arterial plaque group and the femoral arterial plaque group may attribute to the plaque composition. The area and number of macrophages in carotid arterial plaque are higher than those in femoral arterial plaque, while neopterin is secreted by activated macrophage. Except for macrophages, the distribution of other inflammatory molecular markers is different in carotid and femoral atherosclerotic plaques. Regional differences in the hemodynamic profile prime the endothelial phenotype to respond distinctly to such systemic risk factors as hypercholesterolemia, genetics, immune status, and oxidative stress. So neopterin may play a unique role in the process of carotid atherosclerosis, which is different from other vascular territory.

Briefly, after controlling for other confounding factors, neopterin was still an independent predictor for carotid plaque in patients with type 2 diabetes. Migration of
monocyte macrophages through the endothelium represents a key step of atherosclerosis, and the relationship between neopterin and atherosclerosis could be partly explained by the associated activation of macrophages. Oxidative stress seems to play a vital role, because neopterin amplifies the activation of reactive oxygen species mediated cellular processes. De Rosa et al held that activated monocyte macrophages in local atherosclerotic areas obviously increase neopterin levels, thus inducing the expression of adhesion molecules in endothelial cells. These adhesion molecules result in increased binding of lymphocytes, platelets, and other monocytes. Subsequent endothelial activation causes expression of tissue factor, finally leading to the occurrence of atherosclerosis. Nevertheless, the specific molecular mechanisms involved in carotid arterial plaques need to be further studied.

Neopterin is excreted through the kidneys in vivo. We also found that serum neopterin levels were positively correlated with serum creatinine, and negatively correlated with eGFR in patients with type 2 diabetes. Similarly, a prospective cohort study confirmed that the serum creatinine of high-level neopterin increased faster than low-level neopterin group in diabetic nephropathy patients. Spearman correlation analysis showed positive correlations between neopterin levels and BMI as well. Neopterin levels in obese people were higher than in non-obese people, and the level of neopterin decreased after weight loss. Likewise, subjects with WHR >0.9 had higher serum neopterin levels. The association between neopterin and BMI may ascribe to chronic low-grade inflammation in obese people. In this study, we revealed that serum neopterin levels were positively correlated with HOMA-IR, which is consistent with the previous report performed in newly diagnosed patients with T2D who did not take any hypoglycemic agents.

In addition, there are several limitations to be discussed. First of all, our study was based on cross-sectional data with a small sample size from a single center. Prospective studies with larger samples and multiple centers are needed to explore the role of serum neopterin in carotid and lower extremity arterial plaques of type 2 diabetes. Secondly, we did not collect the history of drug therapy, such as insulin, oral hypoglycemic drugs, and other factors which may have impact on atherosclerosis. Finally, atherosclerosis has a complicated pathological process, and it involves many molecular markers. Only one biomarker is not enough to view the whole picture of atherosclerotic plaque formation.

**Conclusions**

We underline that serum neopterin levels were positively and independently associated with carotid plaque in patients with type 2 diabetes. These results also imply that neopterin could be a new therapeutic target both for the prevention and the treatment of carotid plaque.

**Abbreviations**

BMI, body mass index; eGFR, estimated glomerular filtration rate; HDL cholesterol, high-density lipoprotein cholesterol; LDL cholesterol, low-density lipoprotein cholesterol; ACR, urinary albumin-to-creatinine ratio.

**Data Sharing Statement**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Ethics Approval and Consent to Participate**

The study was approved by the ethics committee of the Changhai Hospital, Clinical Research Ethics Committee. Written informed consent was obtained before the data collection and analysis.

**Author Contributions**

All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; agreed to submit to the current journal; gave final approval for the version to be published; and agree to be accountable for all aspects of the work.

**Funding**

This research was supported by research project on aging, maternal, and child health from Shanghai Health Commission (2020YJZX0131), medical innovation research project from Shanghai Science and Technology Committee (20Y11905200) and the project from National Natural Science Foundation of China (81672831).

**Disclosure**

The authors report no conflicts of interest in this work.
References

1. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88–98. doi:10.1038/s41574-2017-1511.

2. Litwak L, Goh SY, Hussein Z, Malek R, Prusty V, Khamseh ME. Prevalence of diabetes complications in people with type 2 diabetes mellitus and its association with baseline characteristics in the multinational A1chieve study. Diabetol Metab Syndr. 2013;5(1):57. doi:10.1186/1758-5966-5-57

3. Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol. 2006;47(5):921–929. doi:10.1016/j.jacc.2005.09.065

4. Forbang NI, McDermott MM, Liao Y, et al. Associations of diabetes mellitus and other cardiovascular disease risk factors with decline in the ankle-brachial index. Vasc Med. 2014;19(6):465–472. doi:10.1177/1358863X14554033

5. Paneni F, Beckman JA, Creager MA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J. 2013;34(31):2436–2443. doi:10.1093/eurheartj/eht149

6. Zheng L-Y, Xu X, Wan R-H, Xia S, Huang Q. Association between serum visfatin levels and atherosclerotic plaque in patients with type 2 diabetes. Diabetol Metab Syndr. 2019;11(1):60. doi:10.1186/s13098-019-0455-5

7. Steven G, Gregory BP, Angus L. Neopterin, Inflammation, and Oxidative Stress: what Could We Be Missing? Antioxidants. 2018;7(7):80. doi:10.3390/antiox7070080

8. Sugioka K, Naruko T, Matsumura Y, et al. Neopterin and atherosclerotic plaque instability in coronary and carotid arteries. J Atheroscler Thromb. 2010;17(11):1115–1121. doi:10.5551/jat.4606

9. Nazer B, Ray KK, Sloan S, et al. Prognostic utility of neopterin and risk of heart failure hospitalization after an acute coronary syndrome. Eur Heart J. 2011;32(11):1390–1397. doi:10.1093/eurheartj/chr032

10. Ray KK, Morrow DA, Sabatine MS, et al. Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome. Circulation. 2007;115(24):3071–3078. doi:10.1161/CIRCULATIONAHA.106.666511

11. Gieseg SP, Crane EM, Flavall EA, Amit Z. Potential to inhibit growth of atherosclerotic plaque development through modulation of macrophage neopterin/7,8-dihydroneopterin synthesis. Br J Pharmacol. 2008;153(4):627–635. doi:10.1038/sj.bjp.0707408

12. Grossmann V, Schmitt VH, Zeller T, et al. Profile of the Immune and Inflammatory Responses in Individuals With Prediabetes and Type 2 Diabetes. Diabetes Care. 2015;38(7):1356–1364. doi:10.2337/dci14-3008

13. Unvirar S, Tanriverdi Z, Aslanli H. Potential Prognostic Role of Immune System Activation Marker Neopterin in Patients with Type 2 Diabetes. J Med Biochem. 2018;37(4):465–469. doi:10.2478/jmmb-2018-0004

14. Lee JE, Oh TJ, Moon JH, Park KS, Jang HC, Choi SH. Serum Neopterin Concentration and Impaired Glucose Metabolism: relationship With beta-Cell Function and Insulin Resistance. Front Endocrinol (Lausanne). 2010;10.439. doi:10.3389/fendo.2019.00043

15. Cuta A, Drugan C, Roman G, Rusu A, Cătană CS. Evaluation of Chitotriosidase and Neopterin as Biomarkers of Microvascular Complications in Patients with Type 1 Diabetes Mellitus. Diagnostics. 2021;11(2):263. doi:10.3390/diagnostics11020263

16. Luu Y, Jiang X, Dai W. The roles of a novel inflammatory neopterin in subjects with coronary atherosclerotic heart disease. Int Immunopharmacol. 2015;24(2):169–172. doi:10.1016/j.intimp.2014.11.013

17. Fredericks S. Neopterin Counters Vascular Inflammation and Atherosclerosis. J Am Heart Assoc. 2018.
